Let's Talk About Cleavage Sites, Patents, DARPA and Moderna

Someone asked me about all of this so I thought I would dust off this old topic and take a bit of a look. I hope you enjoy.

Direct Support

Patreon https://www.patreon.com/americaneveryman
Cash App $scotty6199
Zelle rscdesigns@tampabay.rr.com (Chase bank)

FOLLOW/CONTACT:

Twitch: https://www.twitch.tv/beautender

YouTube https://www.youtube.com/c/scottcreighton1

Substack: https://scottcreighton.substack.com/

website: https://nomadiceveryman.blogspot.com/
BitChute: https://www.bitchute.com

 

 gain of function research pause oct 17 2014 https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwi52uy3v4iEAxX6g4QIHTFsDpo4HhAWegQICBAB&url=https%3A%2F%2Fwww.phe.gov%2Fs3%2Fdualuse%2Fdocuments%2Fgain-of-function.pdf&usg=AOvVaw1pxkg9FsBSI8KvGA_jOpZY&opi=89978449

2017 NIH lifts 3-year ban on funding risky virus studies 

lugar center tblisi georgia aug 2013 https://en.wikipedia.org/wiki/Lugar_Research_Center

(ADEPT-PROTECT) grant DARPA https://www.federalgrants.com/Autonomous-Diagnostics-to-Enable-Prevention-and-Therapeutics-Prophylactic-Options-to-Environmental-and-Contagious-Threats-ADEPT-PROTECT-38431.html

2013 'Moderna also was awarded a $25,000,000 grant by DARPA through a program Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT).^[11] Its stated goal was to develop an mRNA vaccine with the capability to suppress a global pandemic within 60 days.'

'In January 2016, the Bill & Melinda Gates Foundation committed to provide at least $20 million in grant funding to the company'

' In July 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing'

'From 2020 to 2021, Moderna received $955 million from Operation Warp Speed to accelerate development of its COVID-19 vaccine, with $4.9 billion committed in total for producing 300 million vaccine doses'

 

 'RaTG13 has a possible connection to the origins of COVID-19. In April 2012, Chinese miners were assigned to clear bat guano from an abandoned copper mine in southwest China. Six of the miners became ill with what was called a mysterious illness, with three deaths. Researchers from the Wuhan Institute of Virology (WIV) were called in to investigate and collect 276 samples from the bats in the mine. They later identified several new coronaviruses.

The research was led by Shi Zhengli, Ph.D., the WIV’s leading bat coronavirus expert, and published in 2016 in the journal Virologica Sinica. This time in Nature, Shi and colleagues published another paper describing a virus called RaTG13. There was some confusion over whether RaTG13 was from a bat in the mine at the original publication, or whether the virus was RaBtCoV/4991. Shi and colleagues eventually updated the paper in Nature to say they were the same viruses, but they had retested samples from the miners, and they had not been infected with SARS-CoV-2.

SARS-CoV-2 is the only known coronavirus to carry 12 unique amino acids that can be activated by an enzyme called furin. The furin cleavage site is on the virus’s spike protein, which binds to human cells to enter those cells. Researchers add a furin site to viruses in some virology labs to make them more infectious. In the wild, viruses can acquire the furin site by switching genetic code with other viral family members.

Some may view this research as evidence that SARS-CoV-2 originated in the laboratory. It appears to be significantly less precise, and a 19-letter sequence is minimal.

This new report suggests that there is a one-in-three trillion chance Moderna’s sequence randomly showed up via natural evolution, at the very least “is highly unusual and requires further investigations.”

The sequence Moderna patented is part of a gene known as MSHE and is involved in how damaged cells repair themselves. It is a possible target for cancer therapies. Twelve of the 19 amino acids are in SARS-CoV-2’s furin cleavage site, with the remaining seven matching nucleotides in a part of the genome nearby. The researchers suggest that this matching code may have become part of the COVID-19 genome by way of infected human cells expressing the MSH3 gene.' BioSpace

MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site https://www.frontiersin.org/articles/10.3389/fviro.2022.834808/full

Questions Raised over code in Moderna patent 

'Now, a study, MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site, by an international team of scientists that was published in Frontiers in Virology last month, has indirectly raised questions about a patent Moderna was awarded in 2017.

The team found that a tiny piece of genetic code in the coronavirus is identical to part of a gene patented by Moderna well before the onset of the COVID-19 pandemic.

The study's scientists said there is a 1-in-3-trillion chance Moderna's sequence randomly appeared through natural evolution, although others said the occurrence could be coincidental.'

 iuh

 

asdf